Bulletin
Investor Alert

New York Markets Close in:

CRISPR Therapeutics AG

NAS: CRSP

GO
/marketstate/country/us

Market open

/zigman2/quotes/201181046/composite

$

53.34

Change

-1.66 -3.01%

Volume

Volume 354,285

Nov 28, 2022, 1:09 p.m.

Real time quotes

/zigman2/quotes/201181046/composite

Previous close

$ 54.99

$ 53.34

Change

-1.66 -3.01%

Day low

Day high

$53.20

$55.60

Open
Open: 54.97

52 week low

52 week high

$42.51

$86.95

Open

Market cap

$4.31B

Average volume

1.07M

P/E ratio

N/A

Rev. per Employee

$29,791

EPS

-8.80

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/crsp

MarketWatch News on CRSP

  1. Crispr Therapeutics started at underweight with $37 stock price target at Morgan Stanley

    8:41 a.m. Oct. 11, 2022

    - Tomi Kilgore

  2. Crispr Therapeutics stock price target raised to $69 from $55 at Stifel Nicolaus

    6:46 a.m. Aug. 9, 2022

    - Tomi Kilgore

  3. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    3:25 p.m. June 23, 2022

    - Barron's Online

  4. CRISPR Therapeutics downgraded to in line from outperform at Evercore ISI

    5:23 a.m. June 23, 2022

    - Tomi Kilgore

  5. Crispr Therapeutics started at outperform with $98 stock price target at BMO Capital

    11:23 a.m. June 17, 2022

    - Tomi Kilgore

  6. Roku, Tesla, and Other Cathie Wood Favorites Are Falling

    9:21 a.m. June 13, 2022

    - Barron's Online

  7. FDA Advisors Support the First New Gene Therapy in Nearly 5 Years

    4:36 p.m. June 10, 2022

    - Barron's Online

  8. Crispr Therapeutics stock price target cut to $52 from $64 at Stifel Nicolaus

    7:12 a.m. May 10, 2022

    - Tomi Kilgore

  9. Crispr Therapeutics stock price target cut to $100 from $125 at Evercore ISI

    6:44 a.m. Feb. 17, 2022

    - Tomi Kilgore

  10. 20 Bargain Stocks to Buy Now

    7:38 p.m. Jan. 30, 2022

    - Barron's Online

  11. 4 Beaten-Down Biotech Stocks That Could Take Off

    3:07 p.m. Nov. 17, 2021

    - Barron's Online

  12. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  13. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/crsp

Other News on CRSP

  1. ARKK Bears Are Losing Momentum

    8:04 p.m. Nov. 13, 2022

    - Seeking Alpha

  2. GREENWOOD CAPITAL ASSOCIATES LLC Buys 3, Sells 2 in 3rd Quarter

    2:00 p.m. Nov. 10, 2022

    - GuruFocus.com

  3. Nkarta: Under The Radar Company With Brilliant Results

    12:02 p.m. Nov. 10, 2022

    - Seeking Alpha

  4. Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch

    7:45 a.m. Nov. 4, 2022

    - Seeking Alpha

  5. Pfizer: Q3 Earnings Review - Planning For Life After COVID

    2:17 p.m. Nov. 3, 2022

    - Seeking Alpha

  6. This Insider Just Sold Shares of CRISPR Therapeutics AG

    1:30 p.m. Oct. 29, 2022

    - GuruFocus.com

  7. bluebird bio: Commercial Success Highly Uncertain

    6:38 a.m. Oct. 26, 2022

    - Seeking Alpha

  8. Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

    1:34 p.m. Oct. 25, 2022

    - Zacks.com

  9. CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

    12:53 p.m. Oct. 25, 2022

    - Zacks.com

  10. Prime Medicine: CRISPR 3.0 Company

    7:52 p.m. Oct. 24, 2022

    - Seeking Alpha

  11. GNOM: ETF Review And Healthcare Dashboard For October

    7:01 p.m. Oct. 15, 2022

    - Seeking Alpha

  12. Loading more headlines...
/news/pressrelease/company/us/crsp

Press Releases on CRSP

  1. CRISPR Therapeutics to Host Innovation Day on June 21, 2022

    7:00 a.m. May 31, 2022

    - GlobeNewswire

  2. Why Orphan Drug Designation Offers Several Benefits

    7:01 a.m. May 18, 2022

    - Financial News Media

  3. Why Orphan Drug Designation Offers Several Benefits

    7:00 a.m. May 18, 2022

    - PR Newswire - PRF

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.